Sees FY25 revenue $10.7B-$10.85B, consensus $10.67B. Sees FY25 cash provided by operations $1.45B. Sees FY25 capital expenditures $500M. Davis continued: “Our guidance for 2025 reflects our confidence in the core strength of our business, continuing robust utilization, and the momentum from acquisitions completed in 2024. These dynamics position us favorably to accelerate revenue and earnings growth in 2025.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Notable companies reporting before tomorrow’s open
- Quest Diagnostics (DGX) Q4 Earnings Cheat Sheet
- Quest Diagnostics names Adrienne Brott Chief Quality, Regulatory Affairs Officer
- Quest Diagnostics upgraded to Outperform from Market Perform at Leerink
- Quest Diagnostics price target raised to $177 from $174 at Mizuho